Bantam Vape's non-tobacco nicotine e-liquid has been accepted for a premarket tobacco product application (PMTA) submitted by the US Food and Drug Administration.

Bantam's application now enters the next step in the PMTA process - an initial scientific review to confirm that the application contains all required elements to allow substantive review by the FDA.

Bantam submitted its application for a non-tobacco nicotine e-liquid to the FDA on May 13, 2022, and is seeking a marketing order from the agency.

"Receiving this letter of acceptance reflects Bantam's efforts to provide adult consumers with high-quality, science-based e-liquids, while adhering to our responsibility to limit youth access and use of these products," said Bantam spokesman Anthony Dillon. “Bantam remains supportive of the e-liquid industry’s need for science-based regulation and is proud of the progress of our various PMTAs. We are confident in the quality and consistency of our products and the science behind them.”

Bantam submitted a PMTA to the FDA in September 2020 for its tobacco-derived e-liquid, ahead of its non-tobacco nicotine-focused submission. The application entered the scientific review phase in August 2021 and remains under FDA review to date.

Earlier this year, the e-juice maker received a waiver from the United States Postal Service (USPS), allowing the company to ship its e-juice products to select vaping retailers and distributors across the United States.

Prev : California Flavored Tobacco Ban Implemented

Next : Disposable e-cigarette Elf Bars infiltrate UK universities

Email:sales@mlifevapor.com

WhatsApp:+86 13871529372

Email:sales@mlifevapor.com

WhatsApp:+86 13871529372

Tel：+86 13871529372

Add：6 / F, block B, building 2, Fuyong Tongtai times center, Bao'an District, Shenzhen

Language：简体中文 | >

Tel：+86 13871529372

Add：6 / F, block B, building 2, Fuyong Tongtai times center, Bao'an District, Shenzhen Website